Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase I Study to Evaluate the Safety and Efficacy of ORCA-Q Allogeneic Hematopoietic Stem Cell Transplantation for the Treatment of Relapsed/ Refractory High Risk Multiple Myeloma

NCT07759102 is registered in ClinicalTrials.gov with University of California, Davis as lead sponsor.

NCT NCT07759102
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07759102 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase I Study to Evaluate the Safety and Efficacy of ORCA-Q Allogeneic Hematopoietic Stem Cell Transplantation for the Treatment of Relapsed/ Refractory High Risk Multiple Myeloma
Lead sponsor
University of California, Davis
Phase
Phase 1
Overall status
Not yet recruiting
Start date
September 1, 2026
Completion date
September 1, 2033
Enrollment
20 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

recurrent multiple myeloma, refractory multiple myeloma